aml, adult
Showing 1 - 25 of 31
AML, Adult Trial (Pharmacoscopy, Clinical standard-of-care (physician's choice))
Not yet recruiting
- AML, Adult
- Pharmacoscopy
- Clinical standard-of-care (physician's choice)
- (no location specified)
Nov 20, 2023
AML, Adult, Minimal Residual Disease Trial (MRD assessment)
Not yet recruiting
- AML, Adult
- Minimal Residual Disease
- MRD assessment
- (no location specified)
Oct 13, 2023
AML, Adult, Minimal Residual Disease Trial in Guangzhou (chidamide and azacitidine)
Not yet recruiting
- AML, Adult
- Minimal Residual Disease
- chidamide and azacitidine
-
Guangzhou, Guangdong, ChinaGuangdong Provincial People's Hospital
Sep 27, 2023
AML, Adult Trial in Hangzhou (CLL1 CAR-NK cell injection)
Recruiting
- AML, Adult
- CLL1 CAR-NK cell injection
-
Hangzhou, Zhejiang, ChinaClinical research ethics committee of the first affiliated hospi
Aug 30, 2023
AML, Adult, Refractory AML, Relapsed Adult AML Trial in France (AzaCITIDine Oral Tablet, Xospata)
Not yet recruiting
- AML, Adult
- +4 more
- AzaCITIDine Oral Tablet
- Xospata
-
Amiens, France
- +19 more
Sep 1, 2023
AML, Adult, Minimal Residual Disease Trial in Tianjin (CD33/CLL1 dual CAR-NK cell, Cyclophosphamid, Fludarabine)
Not yet recruiting
- AML, Adult
- Minimal Residual Disease
- CD33/CLL1 dual CAR-NK cell
- +5 more
-
Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Aug 4, 2023
Assessment of Geriatric Evaluations Impact on New AML Guidance
Not yet recruiting
- AML, Adult
-
Philadelphia, PennsylvaniaAbramson Cancer Center at University of Pennsylvania
Jun 12, 2023
AML, Adult Trial (Biological characterization of AML with MECOM or atypical 3q26 rearrangements)
Not yet recruiting
- AML, Adult
- Biological characterization of AML with MECOM or atypical 3q26 rearrangements
- (no location specified)
Apr 21, 2023
AML, Adult Trial in Hangzhou (QN-023a, Cyclophosphamid, Fludarabine)
Recruiting
- AML, Adult
- QN-023a
- +4 more
-
Hangzhou, Zhejiang, ChinaThe first affiliated hospital of medical college of zhejiang uni
Dec 29, 2022
AML, Adult Trial in Hangzhou (QN-030a, Cyclophosphamid, Fludarabine)
Recruiting
- AML, Adult
- QN-030a
- +4 more
-
Hangzhou, Zhejiang, ChinaThe first affiliated hospital of medical college of zhejiang uni
Dec 29, 2022
AML, Adult Trial in Tianjin (QN-023a, Cyclophosphamid, Fludarabine)
Recruiting
- AML, Adult
- QN-023a
- +3 more
-
Tianjin, Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Nov 3, 2022
AML, Adult Trial in Berne (HDM201, Midostaurin)
Terminated
- AML, Adult
-
Berne, SwitzerlandDepartement of Medical Oncology, University Hospital Berne
Oct 3, 2022
AML, Adult Trial in Australia, China, United States (APG 2575 ramp up arm)
Recruiting
- AML, Adult
- APG 2575 ramp up arm
-
Baltimore, Maryland
- +6 more
Aug 12, 2022
Acute Myeloid Leukemia, AML, Adult Trial in United States (evorpacept, venetoclax, azacitidine)
Active, not recruiting
- Acute Myeloid Leukemia
- AML, Adult
- evorpacept
- +2 more
-
Chicago, Illinois
- +4 more
Jun 7, 2022
Leukemia, Acute, AML, Adult, ALL, Adult Trial in Charlottesville (Palliative Care Visits)
Recruiting
- Leukemia, Acute
- +3 more
- Palliative Care Visits
-
Charlottesville, VirginiaUniversity of Virginia
Apr 28, 2022
Relapsed/Refractory AML, AML, Adult, MDS Trial in United States (NKX101 - CAR NK cell therapy)
Recruiting
- Relapsed/Refractory AML
- +3 more
- NKX101 - CAR NK cell therapy
-
Denver, Colorado
- +6 more
Apr 8, 2022
AML, Adult, Chemo Effect Trial in Suzhou (Venetoclax, Decitabine for Injection, Cytarabine)
Recruiting
- AML, Adult
- Chemotherapy Effect
- Venetoclax
- +3 more
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University, Jiangsu Ins
Feb 28, 2022